CAJ | 학술논문

目的：观察IZL-2003Ⅱ免疫治疗系统对晚期非小细胞肺癌（ Non-small-cell lung cancer ，NSCLC）化疗患者免疫功能的影响。方法112例晚期NSCLC患者按数字表法随机分为治疗组及对照组，各56例，两组均给予TP方案化疗。治疗组化疗后次日给予IZL-2003Ⅱ免疫治疗系统治疗，连续6 d为1个疗程。对照组单纯化疗。两组化疗前1天及化疗后第8天均行血常规及外周血淋巴细胞免疫功能检测。结果化疗后第8天，治疗组外周血白细胞数明显高于对照组，差异有统计学意义（ P＜0．05）；治疗组CD8＋T细胞治疗前后，差异无统计学意义（P＞0．05）；CD3＋、CD4＋T细胞表达率、CD4＋/CD8＋比值明显高于治疗前，差异有统计学意义（P＜0.05）。对照组CD3＋T细胞表达率治疗前后，差异无统计学意义（P＞0．05）；CD4＋T细胞表达率、CD4＋/CD8＋比值较化疗前明显下降，而 CD8＋T 细胞表达率升高，差异有统计学意义（ P ＜0．05）。结论IZL-2003Ⅱ免疫治疗系统能够减轻化疗对NSCLC患者所致的骨髓抑制，改善化疗后免疫功能抑制，从而提高患者生存质量。
목적：관찰IZL-2003Ⅱ면역치료계통대만기비소세포폐암（ Non-small-cell lung cancer ，NSCLC）화료환자면역공능적영향。방법112례만기NSCLC환자안수자표법수궤분위치료조급대조조，각56례，량조균급여TP방안화료。치료조화료후차일급여IZL-2003Ⅱ면역치료계통치료，련속6 d위1개료정。대조조단순화료。량조화료전1천급화료후제8천균행혈상규급외주혈림파세포면역공능검측。결과화료후제8천，치료조외주혈백세포수명현고우대조조，차이유통계학의의（ P＜0．05）；치료조CD8＋T세포치료전후，차이무통계학의의（P＞0．05）；CD3＋、CD4＋T세포표체솔、CD4＋/CD8＋비치명현고우치료전，차이유통계학의의（P＜0.05）。대조조CD3＋T세포표체솔치료전후，차이무통계학의의（P＞0．05）；CD4＋T세포표체솔、CD4＋/CD8＋비치교화료전명현하강，이 CD8＋T 세포표체솔승고，차이유통계학의의（ P ＜0．05）。결론IZL-2003Ⅱ면역치료계통능구감경화료대NSCLC환자소치적골수억제，개선화료후면역공능억제，종이제고환자생존질량。
Objective To study the effect of IZL-2003Ⅱ Immune Therapy System on lymphocyte immuno-function induced by chemotherapy in advanced non-small-cell lung cancer(NSCLC)patients.Methods 112 cases of advanced NSCLC patients were randomly divided into the two groups .The treatment group ( n=56 ) was given IZL-2003ⅡImmune Therapy System after chemotherapy for 6d as a couse and the control group ( n=56) was given chem-otherapy only.The peripheral blood routine and T lymphocyte subgroup (CD3+,CD4+, CD8+and CD4+/CD8+)activity of patients in both group were measured by flow cytometry 1 day before chemotherapy and the 8th day after chemothera-py.ResultsThere was difference between the treatment group and control group on the increasing rate of Leucocyte (P<0.05)the 8th day after treatment;After the 8th day,the expression levels of CD8+T cells was lower,but has no significant(P<0.05);The expression levels of CD3+,CD4+and the ratio of CD4+/CD8+were higher in the treatment group(P<0.05).The expression levels of CD3+T cells was lower,but has no significant(P<0.05);The expression levels of CD4+T cells and the ratio of CD 4+/CD8+were significantly lower after treatment in control group ( P<0.05);the expression levels of CD8+T cell was higher significantly in the control group (P<0.05).Conclusion IZL-2003ⅡImmune Therapy System can antagonize myelosuppression and elevated the immunologyical function of advanced NSCLC patients significantly .